Phase 1Recruiting

Safety and Tolerability of Metformin and Naproxen for Cancer Prevention in Fanconi Anemia

A Randomized Crossover Open-Label Trial of Naproxen and Metformin Safety and Tolerability in the Setting of Prevention of Oral Cancer in Fanconi Anemia

Sponsor
Rockefeller University (Academic or other)
Enrollment
80 planned
Conditions
Fanconi Anemia; Head and Neck Cancer; Squamous Cell Carcinoma; Squamous Cell Cancer of Head and Neck (SCCHN)
Interventions
Metformin; Naproxen Sodium
Ages
adults, older adults
Registry
NCT07901959

Full record on ClinicalTrials.gov

From the registry

Finding effective ways to slow down or prevent the development of cancer in people with Fanconi anemia (FA) is a critical medical priority. Individuals with FA are at dramatically higher risk of developing aggressive cancers, particularly of the head and neck, and these cancers are difficult to treat with standard therapies such as surgery, chemotherapy or radiation. Because options for treatment are limited and outcomes are often poor, prevention strategies are urgently needed. In this study, the investigators will test two widely available drugs, metformin and naproxen, to evaluate whether they can lower the risk of cancer in FA patients. Metformin is commonly prescribed for type 2 diabetes, while naproxen is a nonsteroidal anti-inflammatory drug (NSAID) frequently used for pain and inflammation. Both have shown potential in previous research to influence biological pathways linked to cancer development. By repurposing these well-known drugs, this trial aims to explore a safe, practical approach to cancer prevention in this vulnerable population. The study, conducted at the…

Primary outcomes

  • Safety
  • Tolerability of Intervention Regimen

History

  1. Study completion expected

  2. Primary completion expected

  3. Registered

  4. Started